• Comprehensive menu in inflammatory diseases and oncology
  • Validated on principle drug and biosimilars
  • Ready to use reagents
  • Standardised protocols from sample collection to result interpretation
  • Automation ready – validated on several open platform ELISA systems

LISA-TRACKER anti-Certolizumab is an enzyme linked immunoassay for the quantitative determination of human anti-Certolizumab pegol antibodies in human serum samples.

Anti-TNFα are therapeutic agents widely used to treat patients with various inflammatory diseases. Certolizumab pegol is one of the anti-TNFα recommended for the treatment of the rheumatoid arthritis. This Fab’ part of humanised monoclonal antibody conjugated to polyethylene glycol is able to bind TNFα, blocking the action of TNFα responsible for the inflammatory state.  However, during the treatment, some patients can develop antibodies against Certolizumab pegol.  Consequently, the plasma level of anti-TNFα decreases and simultaneous the disease symptoms reappear or increase.

  • Arends S et al. The formation of autoantibodies and antibodies to TNF-α blocking agents in relation to clinical response in patients with ankylosing spondylitis. Clin Exp Rheumatol. 2010 Sep-Oct;28(5):661-8.
  • Bendtzen K. Is There a Need for Immunopharmacologic Guidance of Anti–Tumor Necrosis Factor Therapies. ARTHRITIS & RHEUMATISM Vol. 63, No. 4, April 2011, pp 867–870.
  • Choy EHS et al. Efficacy of a novel PEGylated humanized anti-TNF (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose escalating trial. Rheumatology 2002;41:1133-1137.
  • Desroches M et al. Treatment failure with antagonists of TNF-α: mechanisms and implications for the care of patients. Eur. Cytokine Netw., Vol. 21 n° 4, December 2010, 226-31.
  • Edrees AF et al. Anti-tumor necrosis factor (TNF) therapy in rheumatoid arthritis: correlation of TNF-alpha serum level with clinical response and benefit from changing dose or frequency of infliximab infusions. Clin Exp Rheumatol. 2005 Jul-Aug;23(4):469-74.
  • Koren E et al. Recommendation on risk-based strategies for detection and characterization of antibodies against biotechnology products. Journal of Immunological Methods, 333 (2008) 1-9.
  • Mire-Sluis AR et al. Recommendation for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. Journal of Immunological Methods, 289 (2004) 1-16.
  • Ram Raj Singh, & al. TNFα blockade in human diseases: mechanisms and future. Clin.Immunol., 2008 February; 126(2):121-136.
  • Vetterlein O et al. No antibodies to PEG detected in patients treated with certolizumab pegol. Ann Rheum Dis 2008;67(Suppl II):236.

LISA-TRACKER Duo Certolizumab

LISA-TRACKER Certolizumab

ImmunoTROL LISA-TRACKER Certolizumab

ImmunoTROL LISA-TRACKER anti-Certolizumab